

1/9

FIG. 1 SDS PAGE of RSA-FAB' conjugate




FIG. 2 Pharmacokinetics of RSA-Fab' conjugate or controls in the rat





FIG. 3 Pharmacokinetics of RSA-Fab' or Fab'-cys in the rat (assayed by ELISA or cytokine neutralisation)

| PK ANALYSIS - Winnonlin | | | | |
|-------------------------------------|--------------------|-------------------|--------------------|------------------------|
| | $t_{1/2\alpha}(h)$ | $t_{1/2\beta}(h)$ | AUC (0- ∞) | (h \cdot μ g/ml) |
| L929 assay: | | | | |
| RSA-Fab' conjugate | 2.7 | 24.7 | 975 | |
| Fab'-cys | ND | ND | ND | |
| ELISA assay: | | | | |
| RSA-Fab' conjugate (ligand-albumin) | 0.8 | 19.5 | 780 | |
| RSA-Fab' conjugate (ligand-L chain) | 1.3 | 21.6 | 824 | |
| Fab'-cys | ND | 0.7 | 4 | |



4/9

FIG. 4 Construction of pPIC (scFv-HSA)





FIG. 5 Reducing SDS PAGE of HSA-scFv fusion proteins



6/9

FIG. 6 Pharmacokinetics to HSA-Fab' fusion proteins or HSA in the rat






FIG. 7 Structure of trimaleimide crosslinking agent



8/9

FIG. 8 Reducing SDS PAGE of HSA-F(ab')₂ conjugate

9/9

FIG. 9 Scatchard plots of binding of RSA-F(ab')₂ or F(ab')₂ control to cell membranes

